SlideShare ist ein Scribd-Unternehmen logo
1 von 46
Downloaden Sie, um offline zu lesen
ROBERT ORLOWSKI, MD, PhD
Houston, USA
• Professor, Department of Myeloma/Lymphoma, at the
University of Texas MD Anderson Cancer Center
• Dr. Orlowski has published numerous book chapters,
articles, and abstracts on cancer therapy, with a focus on the
molecular pathogenesis of oncologic disease processes and
the mechanisms of action of chemotherapeutics. His clinical
research efforts focus on the translation of promising
laboratory based findings into novel clinical trials for
patients with hematologic malignancies. He has published
in, and is a reviewer for, several journals, including Blood,
Cancer Research, Journal of Clinical Oncology, and the
New England Journal of Medicine. He has received several
awards, including The Leukemia & Lymphoma Society
Scholar in Clinical Research and the Jefferson-Pilot
Fellowship in Academic Medicine.
Recent Updates on Targeted
Therapies for Multiple Myeloma
Robert Z. Orlowski, Ph.D., M.D.
Director, Myeloma Section
Florence Maude Thomas Cancer Research Professor
Departments of Lymphoma/Myeloma & Experimental Therapeutics
Principal Investigator, MD Anderson SPORE in Multiple Myeloma and MD
Anderson Moon Shot in High Risk Myeloma
Chair, SWOG Myeloma Committee
Outline
• Novel targeted small molecules
• Novel targeted monoclonal antibodies
2013 ASH Abstract 285
Prolonged Survival and Improved Response Rates
with ARRY-520 in Relapsed/Refractory Multiple
Myeloma (RRMM) Patients with Low -1 Acidα
Glycoprotein (AAG) Levels : Results From a Phase 2
Study
Sagar Lonial, Jatin J. Shah, Jeffrey Zonder, William I. Bensinger, Adam D. Cohen,
Jonathan L. Kaufman, Ajay K. Nooka, Donna M. Weber, Brandi Hilder, Selena A.
Rush, Ann Ptaszynski, Duncan Walker, and Robert Z. Orlowski
Mechanism of Action
Study Design
Response Data by AAG Levels
Survival Curves
Single-Agent Filanesib
(median 6 previous therapies)
Filanesib + Dex
(median 8 previous therapies)
100
75
50
25
0
0 6 12 18 24 30 36
OS (Mos)
Survival(%)
100
75
50
25
0
0 6 12 18 24 30 36
OS (Mos)
Survival(%)
Low*
High
All
2013 ASH Abstract 1982
Phase 1 Study of the Novel Kinesin Spindle Protein
Inhibitor ARRY-520 + Carfilzomib (Car) in Patients
with Relapsed and/or Refractory Multiple Myeloma
(RRMM)
Jatin J. Shah, Lei Feng, Sheeba K. Thomas, Donna M. Weber, Michael Wang,
Brandi Hilder, Raymond Alexanian, and Robert Z. Orlowski
Trial Design
Initial Efficacy Data
• All patients were bortezomib-refractory
• 63% achieved an MR or better in this phase I
• Growth factor support was not needed after
cycles 1 and 2
2014 ASH Abstract 3453
Oprozomib and Dexamethasone in Patients with
Relapsed and/or Refractory Multiple Myeloma: Initial
Results from the Dose Escalation Portion of a Phase
1b/2, Multicenter, Open-Label Study
Parameswaran N. Hari, Kenneth H. Shain, Peter M. Voorhees, Nashat Gabrail,
Muneer H. Abidi, Jeffrey Zonder, Ralph V. Boccia, Paul G. Richardson, Linda L.
Neuman, Sandra J. Dixon, and Claudia Paba Prada
2014 ASH Abstract 34
Clinical Profile of Single-Agent Oprozomib in Patients
(Pts) with Multiple Myeloma (MM) : Updated Results
from a Multicenter, Open-Label, Dose Escalation
Phase 1b/2 Study
Ravi Vij, Michael Savona, David S. Siegel, Jonathan L. Kaufman, Ashraf Badros,
Irene M. Ghobrial, Agne Paner, Sundar Jagannath, Andrzej Jakubowiak, Joseph R.
Mikhael, Prashant Kapoor, Linda L. Neuman, Ju RueyJiuan Lee, and Jesus G.
Berdeja
Study Design
Hematologic Adverse Events
Other Adverse Events
Response Data
2014 ASH Abstract 301
Phase 1 Study Update of the Novel Pan-Pim Kinase
Inhibitor LGH447 in Patients with Relapsed/
Refractory Multiple Myeloma
Marc S. Raab, Enrique M. Ocio, Sheeba K. Thomas, Andreas Günther, Yeow-Tee
Goh, Daniel Lebovic, Andrzej Jakubowiak, Dongweon Song, F. Xiang, Apurva Patel,
K. Gary Vanasse, and Shaji Kumar
Preclinical Rationale
Garcia, P et al. Blood 122:1666, 2013.
Study Design
• Primary endpoint: MTD/RP2D
• Secondary endpoints: safety, tolerability, preliminary anti-
myeloma activity, pharmacodynamics, pharmacokinetic
profile
Dose Escalation Dose Expansion
MTD/RDE
Relapsed and/or refractory
MM
LGH447 daily, oral
≈ 12 patients
Relapsed and/or
refractory MM
LGH447 daily, oral
70m
g
150m
g
200m
g
250m
g
350m
g
300m
g
500m
g
700m
g
400m
g
Safety
AEs Suspected
Related to Study
Drug Gr 3/4, n (%)
Total
N = 59
Thrombocytopenia 18 (30.5)
Neutropenia 11 (18.6)
WBC decreased 9 (15.2)
Anemia 8 (13.6)
Fatigue 7 (11.9)
Lymphopenia 5 (8.5)
Diarrhea 3 (5.1)
Hyperglycemia 3 (5.1)
Hypophosphatemia 3 (5.1)
• The MTD was 500 mg once
daily
• 10 DLTs: thrombocytopenia
most common (1 pt each @
200-, 250-, 350-, 400-, & 500-
mg); fatigue @ higher doses
(500 & 700 mg)
• Grade 3/4 AEs were mostly
hematologic
• No deaths on study
Efficacy Data
• ORR: 10.5%; CBR: 21.1%; DCR: 71.9%
• Median duration of response was 23.0 weeks
2014 ASH Abstract 31
Ibrutinib, Single Agent or in Combination with
Dexamethasone, in Patients with Relapsed or
Relapsed/Refractory Multiple Myeloma (MM) :
Preliminary Phase 2 Results
Ravi Vij, Carol Ann Huff, William I. Bensinger, David S. Siegel, Sundar Jagannath,
Jesus Berdeja, Nikoletta Lendvai, Daniel Lebovic, Larry D. Anderson Jr., Caitlin L.
Costello, Keith E. Stockerl-Goldstein, Jacob P. Laubach, Laurence Elias, Fong Clow,
Maria Fardis, Thorsten Graef, Elizabeth Bilotti, and Paul G. Richardson
Study Design
Efficacy Data
Outline
• Novel targeted small molecules
• Novel targeted monoclonal antibodies
2014 ASH Abstract 302
Final Results for the 1703 Phase 1b/2 Study of
Elotuzumab in Combination with Lenalidomide and
Dexamethasone in Patients with Relapsed/Refractory
Multiple Myeloma
Paul G. Richardson, Sundar Jagannath, Philippe Moreau, Andrzej Jakubowiak, Marc S.
Raab, Thierry Facon, Ravi Vij, Darrell White, Donna E. Reece, Lotfi Benboubker, Jeffrey
Zonder, L. Claire Tsao, Kenneth C. Anderson, Eric Bleickardt, Anil K. Singhal, and Sagar
Lonial
Preclinical Rationale
Study Design
Response Data
Adverse Event Profile
Infusion Reactions
2014 ASH Abstract 84
Safety and Efficacy of Daratumumab with
Lenalidomide and Dexamethasone in Relapsed or
Relapsed, Refractory Multiple Myeloma
Torben Plesner, Hendrik-Tobias Arkenau, Henk M. Lokhorst, Peter Gimsing, Jakub
Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach,
Tahamtan Ahmadi, Howard Yeh, Mary E. Guckert, Huaibao Feng, Nikolai
Constantin Brun, Steen Lisby, Linda Basse, Antonio Palumbo, and Paul G.
Richardson
Rationale for Targeting CD38
Study Design
Response Curves
Response & Duration on Therapy
Response Rates
Safety Data
Infusion-related Reactions
2014 ASH Abstract 83
A Phase Ib Dose Escalation Trial of SAR650984 (Anti-
CD-38 mAb) in Combination with Lenalidomide and
Dexamethasone in Relapsed/Refractory Multiple
Myeloma
Thomas G. Martin III, Rachid Baz, Don M. Benson Jr., Nikoletta Lendvai, Frank
Campana, Eric Charpentier and Ravi Vij
Patient Population
Efficacy Analysis
Response Durability
Safety Profile
Conclusions
• Oral proteasome inhibitors are moving forward
that will improve patient convenience
• Small molecules targeting new pathways are
showing efficacy, and are in registration studies
• Monoclonal antibodies recognizing myeloma
surface antigens may soon achieve regulatory
approvals
• Additional studies are needed to understand how
these new tools can best be incorporated into our
armamentarium against myeloma

Weitere ähnliche Inhalte

Was ist angesagt?

Ohio State's ASH Review 2017 - Update in Myeloma
Ohio State's ASH Review 2017 - Update in MyelomaOhio State's ASH Review 2017 - Update in Myeloma
Ohio State's ASH Review 2017 - Update in MyelomaOSUCCC - James
 
Familial predisposition for colorectal cancers: Who to screen?
Familial predisposition for colorectal cancers: Who to screen?Familial predisposition for colorectal cancers: Who to screen?
Familial predisposition for colorectal cancers: Who to screen?OSUCCC - James
 
Donor Lymphocyte Infusion: Dr. Chenhua Yan
Donor Lymphocyte Infusion: Dr. Chenhua YanDonor Lymphocyte Infusion: Dr. Chenhua Yan
Donor Lymphocyte Infusion: Dr. Chenhua Yanspa718
 
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...spa718
 
smoldering myeloma
smoldering myelomasmoldering myeloma
smoldering myelomaspa718
 
(Ohio State's 2016 ASH Review) ASH 2015 REVIEW – LYMPHOMA ABSTRACTS
(Ohio State's 2016 ASH Review) ASH 2015 REVIEW – LYMPHOMA ABSTRACTS(Ohio State's 2016 ASH Review) ASH 2015 REVIEW – LYMPHOMA ABSTRACTS
(Ohio State's 2016 ASH Review) ASH 2015 REVIEW – LYMPHOMA ABSTRACTSOSUCCC - James
 
Haematology trials 2017
Haematology trials 2017Haematology trials 2017
Haematology trials 2017Fadel Omar
 
Slide deck updates on cml (1)
Slide deck updates on cml (1)Slide deck updates on cml (1)
Slide deck updates on cml (1)madurai
 
Antiangiogenic Therapy in colorectal cancer
Antiangiogenic Therapy in colorectal cancerAntiangiogenic Therapy in colorectal cancer
Antiangiogenic Therapy in colorectal cancerMohamed Abdulla
 
Elderly AML by Mohamad Mohty
Elderly AML by Mohamad MohtyElderly AML by Mohamad Mohty
Elderly AML by Mohamad Mohtyspa718
 
Dabrafenib Journal Club
Dabrafenib Journal Club Dabrafenib Journal Club
Dabrafenib Journal Club kkorn22
 
Doxorubicin versus Idarubicin with Overall Survival in Adult Acute Myeloid Le...
Doxorubicin versus Idarubicin with Overall Survival in Adult Acute Myeloid Le...Doxorubicin versus Idarubicin with Overall Survival in Adult Acute Myeloid Le...
Doxorubicin versus Idarubicin with Overall Survival in Adult Acute Myeloid Le...Hemat Elgohary
 
Relapsed Myeloma
Relapsed MyelomaRelapsed Myeloma
Relapsed Myelomaspa718
 
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: effica...
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: effica...Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: effica...
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: effica...Enrique Moreno Gonzalez
 
Evidence-Based Practice_Lecture 3_slides
Evidence-Based Practice_Lecture 3_slidesEvidence-Based Practice_Lecture 3_slides
Evidence-Based Practice_Lecture 3_slidesCMDLearning
 

Was ist angesagt? (20)

1 4902328959313641592
1 49023289593136415921 4902328959313641592
1 4902328959313641592
 
Ohio State's ASH Review 2017 - Update in Myeloma
Ohio State's ASH Review 2017 - Update in MyelomaOhio State's ASH Review 2017 - Update in Myeloma
Ohio State's ASH Review 2017 - Update in Myeloma
 
Familial predisposition for colorectal cancers: Who to screen?
Familial predisposition for colorectal cancers: Who to screen?Familial predisposition for colorectal cancers: Who to screen?
Familial predisposition for colorectal cancers: Who to screen?
 
Donor Lymphocyte Infusion: Dr. Chenhua Yan
Donor Lymphocyte Infusion: Dr. Chenhua YanDonor Lymphocyte Infusion: Dr. Chenhua Yan
Donor Lymphocyte Infusion: Dr. Chenhua Yan
 
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
 
International Journal of Neurooncology & Brain Tumors
International Journal of Neurooncology & Brain TumorsInternational Journal of Neurooncology & Brain Tumors
International Journal of Neurooncology & Brain Tumors
 
smoldering myeloma
smoldering myelomasmoldering myeloma
smoldering myeloma
 
paper 4
paper 4paper 4
paper 4
 
(Ohio State's 2016 ASH Review) ASH 2015 REVIEW – LYMPHOMA ABSTRACTS
(Ohio State's 2016 ASH Review) ASH 2015 REVIEW – LYMPHOMA ABSTRACTS(Ohio State's 2016 ASH Review) ASH 2015 REVIEW – LYMPHOMA ABSTRACTS
(Ohio State's 2016 ASH Review) ASH 2015 REVIEW – LYMPHOMA ABSTRACTS
 
Haematology trials 2017
Haematology trials 2017Haematology trials 2017
Haematology trials 2017
 
Slide deck updates on cml (1)
Slide deck updates on cml (1)Slide deck updates on cml (1)
Slide deck updates on cml (1)
 
Antiangiogenic Therapy in colorectal cancer
Antiangiogenic Therapy in colorectal cancerAntiangiogenic Therapy in colorectal cancer
Antiangiogenic Therapy in colorectal cancer
 
CLEVER Final Manuscript_JACC_17Mar2015
CLEVER Final Manuscript_JACC_17Mar2015CLEVER Final Manuscript_JACC_17Mar2015
CLEVER Final Manuscript_JACC_17Mar2015
 
Elderly AML by Mohamad Mohty
Elderly AML by Mohamad MohtyElderly AML by Mohamad Mohty
Elderly AML by Mohamad Mohty
 
Dabrafenib Journal Club
Dabrafenib Journal Club Dabrafenib Journal Club
Dabrafenib Journal Club
 
Doxorubicin versus Idarubicin with Overall Survival in Adult Acute Myeloid Le...
Doxorubicin versus Idarubicin with Overall Survival in Adult Acute Myeloid Le...Doxorubicin versus Idarubicin with Overall Survival in Adult Acute Myeloid Le...
Doxorubicin versus Idarubicin with Overall Survival in Adult Acute Myeloid Le...
 
Relapsed Myeloma
Relapsed MyelomaRelapsed Myeloma
Relapsed Myeloma
 
How I Think, How I Treat: Understanding Innovation in Multiple Myeloma—New Mo...
How I Think, How I Treat: Understanding Innovation in Multiple Myeloma—New Mo...How I Think, How I Treat: Understanding Innovation in Multiple Myeloma—New Mo...
How I Think, How I Treat: Understanding Innovation in Multiple Myeloma—New Mo...
 
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: effica...
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: effica...Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: effica...
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: effica...
 
Evidence-Based Practice_Lecture 3_slides
Evidence-Based Practice_Lecture 3_slidesEvidence-Based Practice_Lecture 3_slides
Evidence-Based Practice_Lecture 3_slides
 

Andere mochten auch

Donor Selection: Sibling. Prof Miguel A Sanz
Donor Selection: Sibling. Prof Miguel A SanzDonor Selection: Sibling. Prof Miguel A Sanz
Donor Selection: Sibling. Prof Miguel A Sanzspa718
 
Prezentácia produktov 2
Prezentácia produktov 2Prezentácia produktov 2
Prezentácia produktov 2kozivrsok
 
โครงงานคอมพ วเตอร
โครงงานคอมพ วเตอร โครงงานคอมพ วเตอร
โครงงานคอมพ วเตอร I'am Jimmy
 
Australian seo packages
Australian seo packagesAustralian seo packages
Australian seo packagesAbhi Chauhan
 
Presentation 1 cond.
Presentation 1 cond.Presentation 1 cond.
Presentation 1 cond.lzanel
 
Presentació Polònia
Presentació PolòniaPresentació Polònia
Presentació Polòniajordimatgespix
 
Pre AP LA Curriculum Night
Pre AP LA Curriculum NightPre AP LA Curriculum Night
Pre AP LA Curriculum Nightmboydeast703
 
Elements of story telling xD
Elements of story telling xDElements of story telling xD
Elements of story telling xDkameanne
 
Michael Durante Western Reserve Blackwall Partners Camel Race
Michael Durante Western Reserve Blackwall Partners Camel RaceMichael Durante Western Reserve Blackwall Partners Camel Race
Michael Durante Western Reserve Blackwall Partners Camel RaceMichael Durante
 
Presentation Terqua
Presentation TerquaPresentation Terqua
Presentation Terquabfdzizu
 
Mgmt306 first year powerpoint
Mgmt306 first year powerpointMgmt306 first year powerpoint
Mgmt306 first year powerpointSbrewer306
 
Oleg gochev-2014.eng-1
Oleg gochev-2014.eng-1Oleg gochev-2014.eng-1
Oleg gochev-2014.eng-1Sim Aleksiev
 
Michał Mętlewicz - Czy współpraca z vlogerami się opłaca? Case study Level77.pl.
Michał Mętlewicz - Czy współpraca z vlogerami się opłaca? Case study Level77.pl.Michał Mętlewicz - Czy współpraca z vlogerami się opłaca? Case study Level77.pl.
Michał Mętlewicz - Czy współpraca z vlogerami się opłaca? Case study Level77.pl.#e-biznes festiwal
 
Newsletter 6 pdf
Newsletter 6  pdfNewsletter 6  pdf
Newsletter 6 pdfmaymaskow1
 
Presentazione Bilancio Informatica Solidale - Assemblea Febbraio 2014
Presentazione Bilancio Informatica Solidale - Assemblea Febbraio 2014Presentazione Bilancio Informatica Solidale - Assemblea Febbraio 2014
Presentazione Bilancio Informatica Solidale - Assemblea Febbraio 2014Claudio Tancini
 

Andere mochten auch (20)

Donor Selection: Sibling. Prof Miguel A Sanz
Donor Selection: Sibling. Prof Miguel A SanzDonor Selection: Sibling. Prof Miguel A Sanz
Donor Selection: Sibling. Prof Miguel A Sanz
 
Prezentácia produktov 2
Prezentácia produktov 2Prezentácia produktov 2
Prezentácia produktov 2
 
โครงงานคอมพ วเตอร
โครงงานคอมพ วเตอร โครงงานคอมพ วเตอร
โครงงานคอมพ วเตอร
 
พรีเซนต์
พรีเซนต์พรีเซนต์
พรีเซนต์
 
Australian seo packages
Australian seo packagesAustralian seo packages
Australian seo packages
 
Scrumprimer20
Scrumprimer20Scrumprimer20
Scrumprimer20
 
Presentation 1 cond.
Presentation 1 cond.Presentation 1 cond.
Presentation 1 cond.
 
Las vegas boudoir photography
Las vegas boudoir photographyLas vegas boudoir photography
Las vegas boudoir photography
 
Presentació Polònia
Presentació PolòniaPresentació Polònia
Presentació Polònia
 
Pre AP LA Curriculum Night
Pre AP LA Curriculum NightPre AP LA Curriculum Night
Pre AP LA Curriculum Night
 
corso comunicazione digitale e social network
corso comunicazione digitale e social networkcorso comunicazione digitale e social network
corso comunicazione digitale e social network
 
Elements of story telling xD
Elements of story telling xDElements of story telling xD
Elements of story telling xD
 
Michael Durante Western Reserve Blackwall Partners Camel Race
Michael Durante Western Reserve Blackwall Partners Camel RaceMichael Durante Western Reserve Blackwall Partners Camel Race
Michael Durante Western Reserve Blackwall Partners Camel Race
 
Presentation Terqua
Presentation TerquaPresentation Terqua
Presentation Terqua
 
Mgmt306 first year powerpoint
Mgmt306 first year powerpointMgmt306 first year powerpoint
Mgmt306 first year powerpoint
 
Oleg gochev-2014.eng-1
Oleg gochev-2014.eng-1Oleg gochev-2014.eng-1
Oleg gochev-2014.eng-1
 
Lasvegasfoodphotography
LasvegasfoodphotographyLasvegasfoodphotography
Lasvegasfoodphotography
 
Michał Mętlewicz - Czy współpraca z vlogerami się opłaca? Case study Level77.pl.
Michał Mętlewicz - Czy współpraca z vlogerami się opłaca? Case study Level77.pl.Michał Mętlewicz - Czy współpraca z vlogerami się opłaca? Case study Level77.pl.
Michał Mętlewicz - Czy współpraca z vlogerami się opłaca? Case study Level77.pl.
 
Newsletter 6 pdf
Newsletter 6  pdfNewsletter 6  pdf
Newsletter 6 pdf
 
Presentazione Bilancio Informatica Solidale - Assemblea Febbraio 2014
Presentazione Bilancio Informatica Solidale - Assemblea Febbraio 2014Presentazione Bilancio Informatica Solidale - Assemblea Febbraio 2014
Presentazione Bilancio Informatica Solidale - Assemblea Febbraio 2014
 

Ähnlich wie 1 orlowski targeted-therapies

11 orlowski lunch-symposium_final
11 orlowski lunch-symposium_final11 orlowski lunch-symposium_final
11 orlowski lunch-symposium_finalspa718
 
Newly Diagnosed Myeloma
Newly Diagnosed MyelomaNewly Diagnosed Myeloma
Newly Diagnosed Myelomaspa718
 
metastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storymetastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storyMohamed Abdulla
 
Identification and Characterization of Drug (3)
Identification and Characterization of Drug (3)Identification and Characterization of Drug (3)
Identification and Characterization of Drug (3)Alina Amitai ????? ?????
 
Novel Strategies for Attacking the Epidermal Growth Factor Receptor
Novel Strategies for Attacking the Epidermal Growth Factor ReceptorNovel Strategies for Attacking the Epidermal Growth Factor Receptor
Novel Strategies for Attacking the Epidermal Growth Factor ReceptorOSUCCC - James
 
Safety and clinical activity of pembrolizumab for treatment
Safety and clinical activity of pembrolizumab for treatmentSafety and clinical activity of pembrolizumab for treatment
Safety and clinical activity of pembrolizumab for treatmentMarwa EL-Sayed
 
Ohio State's ASH Review 2017 - Benign Hematology
Ohio State's ASH Review 2017 - Benign HematologyOhio State's ASH Review 2017 - Benign Hematology
Ohio State's ASH Review 2017 - Benign HematologyOSUCCC - James
 
Unmet need in multiple myeloma
Unmet need in multiple myelomaUnmet need in multiple myeloma
Unmet need in multiple myelomaPLMMedical
 
Her2 nact aug 20 - copy
Her2 nact  aug 20 - copyHer2 nact  aug 20 - copy
Her2 nact aug 20 - copymadurai
 
METASTATC COLORECTAL CANCER IN 2017
METASTATC COLORECTAL CANCER IN 2017METASTATC COLORECTAL CANCER IN 2017
METASTATC COLORECTAL CANCER IN 2017Mohamed Abdulla
 
Management of metastatic colorectal cancer
Management of metastatic colorectal cancerManagement of metastatic colorectal cancer
Management of metastatic colorectal cancerMohamed Abdulla
 
4 ΟΓΚΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ ΡΟΔΟΥ
4 ΟΓΚΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ ΡΟΔΟΥ4 ΟΓΚΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ ΡΟΔΟΥ
4 ΟΓΚΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ ΡΟΔΟΥisrodoy isr
 
PROGNOSTIC VALUE OF PERIPHERAL BLOOD BLAST PERCENTAGE ON DAY 8 IN LONG TERM ...
PROGNOSTIC VALUE OF PERIPHERAL BLOOD BLAST  PERCENTAGE ON DAY 8 IN LONG TERM ...PROGNOSTIC VALUE OF PERIPHERAL BLOOD BLAST  PERCENTAGE ON DAY 8 IN LONG TERM ...
PROGNOSTIC VALUE OF PERIPHERAL BLOOD BLAST PERCENTAGE ON DAY 8 IN LONG TERM ...NeetiVaghela
 
Giải pháp cho người bị hói
Giải pháp cho người bị hóiGiải pháp cho người bị hói
Giải pháp cho người bị hóihieusach-kimnhung
 
The Latest Treatments for HER2-Positive Breast Cancer
The Latest Treatments for HER2-Positive Breast CancerThe Latest Treatments for HER2-Positive Breast Cancer
The Latest Treatments for HER2-Positive Breast CancerDana-Farber Cancer Institute
 
Sequencing Agents in Metastatic Prostate Cancer
Sequencing Agents in Metastatic Prostate CancerSequencing Agents in Metastatic Prostate Cancer
Sequencing Agents in Metastatic Prostate Cancerflasco_org
 

Ähnlich wie 1 orlowski targeted-therapies (20)

11 orlowski lunch-symposium_final
11 orlowski lunch-symposium_final11 orlowski lunch-symposium_final
11 orlowski lunch-symposium_final
 
Newly Diagnosed Myeloma
Newly Diagnosed MyelomaNewly Diagnosed Myeloma
Newly Diagnosed Myeloma
 
mycv2016
mycv2016mycv2016
mycv2016
 
metastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storymetastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the story
 
Identification and Characterization of Drug (3)
Identification and Characterization of Drug (3)Identification and Characterization of Drug (3)
Identification and Characterization of Drug (3)
 
Novel Strategies for Attacking the Epidermal Growth Factor Receptor
Novel Strategies for Attacking the Epidermal Growth Factor ReceptorNovel Strategies for Attacking the Epidermal Growth Factor Receptor
Novel Strategies for Attacking the Epidermal Growth Factor Receptor
 
Safety and clinical activity of pembrolizumab for treatment
Safety and clinical activity of pembrolizumab for treatmentSafety and clinical activity of pembrolizumab for treatment
Safety and clinical activity of pembrolizumab for treatment
 
Ohio State's ASH Review 2017 - Benign Hematology
Ohio State's ASH Review 2017 - Benign HematologyOhio State's ASH Review 2017 - Benign Hematology
Ohio State's ASH Review 2017 - Benign Hematology
 
Unmet need in multiple myeloma
Unmet need in multiple myelomaUnmet need in multiple myeloma
Unmet need in multiple myeloma
 
Her2 nact aug 20 - copy
Her2 nact  aug 20 - copyHer2 nact  aug 20 - copy
Her2 nact aug 20 - copy
 
METASTATC COLORECTAL CANCER IN 2017
METASTATC COLORECTAL CANCER IN 2017METASTATC COLORECTAL CANCER IN 2017
METASTATC COLORECTAL CANCER IN 2017
 
Management of metastatic colorectal cancer
Management of metastatic colorectal cancerManagement of metastatic colorectal cancer
Management of metastatic colorectal cancer
 
4 ΟΓΚΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ ΡΟΔΟΥ
4 ΟΓΚΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ ΡΟΔΟΥ4 ΟΓΚΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ ΡΟΔΟΥ
4 ΟΓΚΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ ΡΟΔΟΥ
 
PROGNOSTIC VALUE OF PERIPHERAL BLOOD BLAST PERCENTAGE ON DAY 8 IN LONG TERM ...
PROGNOSTIC VALUE OF PERIPHERAL BLOOD BLAST  PERCENTAGE ON DAY 8 IN LONG TERM ...PROGNOSTIC VALUE OF PERIPHERAL BLOOD BLAST  PERCENTAGE ON DAY 8 IN LONG TERM ...
PROGNOSTIC VALUE OF PERIPHERAL BLOOD BLAST PERCENTAGE ON DAY 8 IN LONG TERM ...
 
JAMA-PDE5i in heart failure
JAMA-PDE5i in heart failureJAMA-PDE5i in heart failure
JAMA-PDE5i in heart failure
 
Rhabdomyosarcoma Of head and neck
Rhabdomyosarcoma Of head and neckRhabdomyosarcoma Of head and neck
Rhabdomyosarcoma Of head and neck
 
Marsh pers strat-mednov2014
Marsh pers strat-mednov2014Marsh pers strat-mednov2014
Marsh pers strat-mednov2014
 
Giải pháp cho người bị hói
Giải pháp cho người bị hóiGiải pháp cho người bị hói
Giải pháp cho người bị hói
 
The Latest Treatments for HER2-Positive Breast Cancer
The Latest Treatments for HER2-Positive Breast CancerThe Latest Treatments for HER2-Positive Breast Cancer
The Latest Treatments for HER2-Positive Breast Cancer
 
Sequencing Agents in Metastatic Prostate Cancer
Sequencing Agents in Metastatic Prostate CancerSequencing Agents in Metastatic Prostate Cancer
Sequencing Agents in Metastatic Prostate Cancer
 

Mehr von spa718

1600 1620 siwanon jirawatnotai
1600 1620 siwanon jirawatnotai1600 1620 siwanon jirawatnotai
1600 1620 siwanon jirawatnotaispa718
 
Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery spa718
 
Controversies in Colorectal Cancer
Controversies in Colorectal CancerControversies in Colorectal Cancer
Controversies in Colorectal Cancerspa718
 
Pancreatic Cancer
Pancreatic CancerPancreatic Cancer
Pancreatic Cancerspa718
 
Chemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancerChemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancerspa718
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinomaspa718
 
Immunotherapy for Colorectal Cancer
Immunotherapy for Colorectal CancerImmunotherapy for Colorectal Cancer
Immunotherapy for Colorectal Cancerspa718
 
Surgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung CancerSurgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung Cancerspa718
 
Role of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung CancerRole of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung Cancerspa718
 
Update on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast CancerUpdate on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast Cancerspa718
 
Technical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) CancerTechnical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) Cancerspa718
 
Controversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast CancerControversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast Cancerspa718
 
ImmunoOncology in Lung Cancer
ImmunoOncology in Lung CancerImmunoOncology in Lung Cancer
ImmunoOncology in Lung Cancerspa718
 
Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015spa718
 
Updates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast CancerUpdates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast Cancerspa718
 
Regulatory T Cells and GVHD
Regulatory T Cells and GVHDRegulatory T Cells and GVHD
Regulatory T Cells and GVHDspa718
 
Immunotherapy for Multiple Myeloma
Immunotherapy for Multiple MyelomaImmunotherapy for Multiple Myeloma
Immunotherapy for Multiple Myelomaspa718
 
NHL immunotherapy
NHL immunotherapyNHL immunotherapy
NHL immunotherapyspa718
 
AML and Cell Therapy
AML and Cell TherapyAML and Cell Therapy
AML and Cell Therapyspa718
 
Acute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment UpdateAcute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment Updatespa718
 

Mehr von spa718 (20)

1600 1620 siwanon jirawatnotai
1600 1620 siwanon jirawatnotai1600 1620 siwanon jirawatnotai
1600 1620 siwanon jirawatnotai
 
Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery Controversies in hepato-biliary surgery
Controversies in hepato-biliary surgery
 
Controversies in Colorectal Cancer
Controversies in Colorectal CancerControversies in Colorectal Cancer
Controversies in Colorectal Cancer
 
Pancreatic Cancer
Pancreatic CancerPancreatic Cancer
Pancreatic Cancer
 
Chemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancerChemoradiation vs Surgery for rectal cancer
Chemoradiation vs Surgery for rectal cancer
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinoma
 
Immunotherapy for Colorectal Cancer
Immunotherapy for Colorectal CancerImmunotherapy for Colorectal Cancer
Immunotherapy for Colorectal Cancer
 
Surgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung CancerSurgical Approach to Non Small Cell Lung Cancer
Surgical Approach to Non Small Cell Lung Cancer
 
Role of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung CancerRole of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung Cancer
 
Update on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast CancerUpdate on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast Cancer
 
Technical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) CancerTechnical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) Cancer
 
Controversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast CancerControversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast Cancer
 
ImmunoOncology in Lung Cancer
ImmunoOncology in Lung CancerImmunoOncology in Lung Cancer
ImmunoOncology in Lung Cancer
 
Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015Breast Cancer Highlights: ASCO 2015
Breast Cancer Highlights: ASCO 2015
 
Updates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast CancerUpdates in Radiotherapy for Breast Cancer
Updates in Radiotherapy for Breast Cancer
 
Regulatory T Cells and GVHD
Regulatory T Cells and GVHDRegulatory T Cells and GVHD
Regulatory T Cells and GVHD
 
Immunotherapy for Multiple Myeloma
Immunotherapy for Multiple MyelomaImmunotherapy for Multiple Myeloma
Immunotherapy for Multiple Myeloma
 
NHL immunotherapy
NHL immunotherapyNHL immunotherapy
NHL immunotherapy
 
AML and Cell Therapy
AML and Cell TherapyAML and Cell Therapy
AML and Cell Therapy
 
Acute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment UpdateAcute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment Update
 

1 orlowski targeted-therapies

  • 1. ROBERT ORLOWSKI, MD, PhD Houston, USA • Professor, Department of Myeloma/Lymphoma, at the University of Texas MD Anderson Cancer Center • Dr. Orlowski has published numerous book chapters, articles, and abstracts on cancer therapy, with a focus on the molecular pathogenesis of oncologic disease processes and the mechanisms of action of chemotherapeutics. His clinical research efforts focus on the translation of promising laboratory based findings into novel clinical trials for patients with hematologic malignancies. He has published in, and is a reviewer for, several journals, including Blood, Cancer Research, Journal of Clinical Oncology, and the New England Journal of Medicine. He has received several awards, including The Leukemia & Lymphoma Society Scholar in Clinical Research and the Jefferson-Pilot Fellowship in Academic Medicine.
  • 2. Recent Updates on Targeted Therapies for Multiple Myeloma Robert Z. Orlowski, Ph.D., M.D. Director, Myeloma Section Florence Maude Thomas Cancer Research Professor Departments of Lymphoma/Myeloma & Experimental Therapeutics Principal Investigator, MD Anderson SPORE in Multiple Myeloma and MD Anderson Moon Shot in High Risk Myeloma Chair, SWOG Myeloma Committee
  • 3. Outline • Novel targeted small molecules • Novel targeted monoclonal antibodies
  • 4. 2013 ASH Abstract 285 Prolonged Survival and Improved Response Rates with ARRY-520 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with Low -1 Acidα Glycoprotein (AAG) Levels : Results From a Phase 2 Study Sagar Lonial, Jatin J. Shah, Jeffrey Zonder, William I. Bensinger, Adam D. Cohen, Jonathan L. Kaufman, Ajay K. Nooka, Donna M. Weber, Brandi Hilder, Selena A. Rush, Ann Ptaszynski, Duncan Walker, and Robert Z. Orlowski
  • 7. Response Data by AAG Levels
  • 8. Survival Curves Single-Agent Filanesib (median 6 previous therapies) Filanesib + Dex (median 8 previous therapies) 100 75 50 25 0 0 6 12 18 24 30 36 OS (Mos) Survival(%) 100 75 50 25 0 0 6 12 18 24 30 36 OS (Mos) Survival(%) Low* High All
  • 9. 2013 ASH Abstract 1982 Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) Jatin J. Shah, Lei Feng, Sheeba K. Thomas, Donna M. Weber, Michael Wang, Brandi Hilder, Raymond Alexanian, and Robert Z. Orlowski
  • 11. Initial Efficacy Data • All patients were bortezomib-refractory • 63% achieved an MR or better in this phase I • Growth factor support was not needed after cycles 1 and 2
  • 12. 2014 ASH Abstract 3453 Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study Parameswaran N. Hari, Kenneth H. Shain, Peter M. Voorhees, Nashat Gabrail, Muneer H. Abidi, Jeffrey Zonder, Ralph V. Boccia, Paul G. Richardson, Linda L. Neuman, Sandra J. Dixon, and Claudia Paba Prada
  • 13. 2014 ASH Abstract 34 Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM) : Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study Ravi Vij, Michael Savona, David S. Siegel, Jonathan L. Kaufman, Ashraf Badros, Irene M. Ghobrial, Agne Paner, Sundar Jagannath, Andrzej Jakubowiak, Joseph R. Mikhael, Prashant Kapoor, Linda L. Neuman, Ju RueyJiuan Lee, and Jesus G. Berdeja
  • 18. 2014 ASH Abstract 301 Phase 1 Study Update of the Novel Pan-Pim Kinase Inhibitor LGH447 in Patients with Relapsed/ Refractory Multiple Myeloma Marc S. Raab, Enrique M. Ocio, Sheeba K. Thomas, Andreas Günther, Yeow-Tee Goh, Daniel Lebovic, Andrzej Jakubowiak, Dongweon Song, F. Xiang, Apurva Patel, K. Gary Vanasse, and Shaji Kumar
  • 19. Preclinical Rationale Garcia, P et al. Blood 122:1666, 2013.
  • 20. Study Design • Primary endpoint: MTD/RP2D • Secondary endpoints: safety, tolerability, preliminary anti- myeloma activity, pharmacodynamics, pharmacokinetic profile Dose Escalation Dose Expansion MTD/RDE Relapsed and/or refractory MM LGH447 daily, oral ≈ 12 patients Relapsed and/or refractory MM LGH447 daily, oral 70m g 150m g 200m g 250m g 350m g 300m g 500m g 700m g 400m g
  • 21. Safety AEs Suspected Related to Study Drug Gr 3/4, n (%) Total N = 59 Thrombocytopenia 18 (30.5) Neutropenia 11 (18.6) WBC decreased 9 (15.2) Anemia 8 (13.6) Fatigue 7 (11.9) Lymphopenia 5 (8.5) Diarrhea 3 (5.1) Hyperglycemia 3 (5.1) Hypophosphatemia 3 (5.1) • The MTD was 500 mg once daily • 10 DLTs: thrombocytopenia most common (1 pt each @ 200-, 250-, 350-, 400-, & 500- mg); fatigue @ higher doses (500 & 700 mg) • Grade 3/4 AEs were mostly hematologic • No deaths on study
  • 22. Efficacy Data • ORR: 10.5%; CBR: 21.1%; DCR: 71.9% • Median duration of response was 23.0 weeks
  • 23. 2014 ASH Abstract 31 Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM) : Preliminary Phase 2 Results Ravi Vij, Carol Ann Huff, William I. Bensinger, David S. Siegel, Sundar Jagannath, Jesus Berdeja, Nikoletta Lendvai, Daniel Lebovic, Larry D. Anderson Jr., Caitlin L. Costello, Keith E. Stockerl-Goldstein, Jacob P. Laubach, Laurence Elias, Fong Clow, Maria Fardis, Thorsten Graef, Elizabeth Bilotti, and Paul G. Richardson
  • 26. Outline • Novel targeted small molecules • Novel targeted monoclonal antibodies
  • 27. 2014 ASH Abstract 302 Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Paul G. Richardson, Sundar Jagannath, Philippe Moreau, Andrzej Jakubowiak, Marc S. Raab, Thierry Facon, Ravi Vij, Darrell White, Donna E. Reece, Lotfi Benboubker, Jeffrey Zonder, L. Claire Tsao, Kenneth C. Anderson, Eric Bleickardt, Anil K. Singhal, and Sagar Lonial
  • 33. 2014 ASH Abstract 84 Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma Torben Plesner, Hendrik-Tobias Arkenau, Henk M. Lokhorst, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, Tahamtan Ahmadi, Howard Yeh, Mary E. Guckert, Huaibao Feng, Nikolai Constantin Brun, Steen Lisby, Linda Basse, Antonio Palumbo, and Paul G. Richardson
  • 37. Response & Duration on Therapy
  • 41. 2014 ASH Abstract 83 A Phase Ib Dose Escalation Trial of SAR650984 (Anti- CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Thomas G. Martin III, Rachid Baz, Don M. Benson Jr., Nikoletta Lendvai, Frank Campana, Eric Charpentier and Ravi Vij
  • 46. Conclusions • Oral proteasome inhibitors are moving forward that will improve patient convenience • Small molecules targeting new pathways are showing efficacy, and are in registration studies • Monoclonal antibodies recognizing myeloma surface antigens may soon achieve regulatory approvals • Additional studies are needed to understand how these new tools can best be incorporated into our armamentarium against myeloma